Rapid kinetic characterization for inhibition assays

Rapid kinetic characterization for inhibition assays

Binding kinetics provide the full picture in biologics development

Sybody® candidates compete for ACE2 binding onto SARS-CoV-2 Spike RBD

With no-clog microfluidics and superior sensitivity to conventional Surface Plasmon Resonance (SPR) technologies for more accurate measurement of binding affinity and binding kinetics, here we show how the WAVEsystem is driving biologics development by providing insights into binding affinities and selectivity of Sybody® candidates to the receptor-binding domain (RBD) region of SARS-CoV-2 Spike protein

  • Sybody® characterization

    Identify Sybody® candidates binding to RBD domain of SARS-CoV-2 via off-rate screening

  • Fast inhibition studies

    Discover how Sybody® candidates inhibit the ACE2-Spike RBD interaction

  • ELISA validation

    Cross validate ELISA data

High sensitivity and robust microfluidics

With high sensitivity and robust microfluidics, the WAVEsystem is suitable for competition assays, confirming and enriching ELISA data. By providing a rapid kinetic characterization for inhibition assays, with ACE2 kindly provided by leadXpro, the WAVE is accelerating the development of therapeutics against SARS-CoV-2.

  • The experiments behind TechNote 14


    Listen to Markus Seeger and Rony Nehmé discuss their collaboration in detail, including why ELISA signals alone cannot predict potency, Markus choice for the WAVEsystem and why it is important to choose the right candidates at the very early stages of research.

  • Experimental details

    TechNote 14

    In this TechNote we show how the WAVEsystem can be used to understand the binding dynamics of Sybody® candidates to the receptor binding domain (RBD) of SARS-CoV-2, both provided by Linkster Therapeutics AG and the University of Zürich.

  • bioRxiv, 2020


    J. D. Walter, C. A. .J. Hutter, I. Zimmermann, M. Wyss, P. Egloff, M. Sorgenfrei, L. M. Hürlimann, I. Gonda, G. Meier, S. Remm, S. Thavarasah, P. Plattet, M. A. Seeger. “Sybodies targeting the SARS-CoV-2 receptor-binding domain.”

Thorough testing in our laboratory has convinced us that Creoptix’ WAVE technology aids us best in discovering better drug molecules

Nicolas Bocquet

Nicolas Bocquet,

Senior Scientist at leadXpro